Piramal Pharma shares climbed over 3% after the US FDA issued an Establishment Inspection Report for its Sellersville facility. This clearance removes a significant regulatory uncertainty for the company. Investors should note that while this is positive, the broader pharmaceutical sector faces potential earnings pressure due to a high base in the US market.
Piramal Pharma Limited shares saw a positive move in Thursday's session, rising over 3% to reach an intraday high of Rs 173.59 on the BSE. This movement follows the company's announcement that the US Food and Drug Administration (FDA) has officially closed the inspection of its manufacturing plant in Sellersville, Pennsylvania.
In a filing with the stock exchanges, the company confirmed it received an Establishment Inspection Report (EIR). Receiving an EIR is a standard but critical regulatory milestone that signals the successful completion of an inspection process, confirming that the facility meets the necessary quality and compliance standards required to operate in the US market.
The Sellersville site had been under regulatory watch since the company notified the exchanges about an ongoing inspection on May 10, 2026. With this closure, the company eliminates a specific area of uncertainty that often weighs on investor sentiment for pharmaceutical exporters. Ensuring smooth regulatory status for US-facing plants is essential for maintaining consistent export volumes and avoiding potential supply disruptions.
While the regulatory clearance is a positive development for Piramal Pharma, the broader pharmaceutical sector is currently navigating complex market dynamics. Brokerage firm PL Capital has indicated that overall earnings for the June quarter might remain muted across the industry. The firm projects modest EBITDA growth of about 1% year-on-year, largely due to a high sales base in the US market from the previous year.
Despite these challenges, domestic formulations are expected to remain a steadying factor. Factors such as a potential recovery in acute therapy demand and continued growth in chronic therapies are likely to support domestic performance. Furthermore, investors are tracking the impact of new generic drug launches, such as semaglutide, which may influence revenue in the coming quarters.
For major players in the sector, including peers like Torrent Pharmaceuticals, Lupin, and Divi's Laboratories, growth paths remain tied to both product mix and cost management. Companies with significant exposure to the US may continue to experience pressure on profit margins if they face an unfavorable product mix or the impact of high-base legacy products like gRevlimid. Investors may continue to monitor the company’s quarterly results to see how domestic growth and stabilized US manufacturing operations impact the overall bottom line.